Everything You Need To Know About 23andMe In One Place
23andMe is an impressive DNA testing provider featuring a staggering user count, paired with cutting-edge tools for chromosome browsing, biogeographical ancestry analysis, and health-related results. Read all about this exceptional service in our detailed 23andMe review.
If you suspect Ashkenazi Jewish ancestry on either side of your family, performing a DNA test to confirm it and determine your carrier status for dangerous hereditary diseases is essential, especially if you are thinking about starting a family. Read this analysis to learn how 23andMe’s ancestry and health tests can help you with your genetic exploration.
23andMe has just introduced its first in-house drug licensed to a Spanish drug company named Almirall. The drug was designed to target inflammatory processes and autoimmune conditions. Read this brief report to learn more about the drug itself as well as 23andMe’s plans for the future in pharmacology.
The most important questions when it comes to adoptees and popular at-home DNA testing services is whether DNA tests can identify one’s biological parents and tell them more about their ancestry and genetic origins. Read this brief analysis to learn if 23andMe can answer these questions for you.
23andMe Black Friday deals for 2019 present you with the perfect opportunity to grab the DNA testing provider’s at-home ancestry and health-related kits and explore your genetic heritage across 1,500+ regions, potential carrier status for more than 40 conditions, inherited genetic traits, and much more.
23andMe, the most popular at-home DNA testing provider, recently announced the implementation of auto-populating family trees paired with a significant expansion of its Western Asian, South Asian, and North African regions. Read this comprehensive report to find out more about these changes and learn what they mean for 23andMe users.
23andMe, Ancestry, and Helix have formed a Privacy Coalition and released a whitepaper outlining the best practices for managing sensitive genetic data obtained from their customers. Congress is also drafting a bill that would legislate the issue on a federal level. Read more in this comprehensive report.
23andMe has joined forces with The Michael J. Fox Foundation in efforts to provide further insight into Parkinson’s disease through a new tool called Fox DEN (Fox Insight Data Exploration Network) designed to use customer-reported data in 23andMe’s database and combine it with genetic information. Read more in this article.
23andMe’s genetic database provided the necessary samples for the latest study related to genetic prerequisites for low bone density and the development of osteoporosis. The main goal of the study was to find the causal connection between the genetic variations and the illness and help develop potential treatments and identify patients earlier.
After clearing its test for three variants in BRCA1 and BRCA2 genes related to breast cancer, the FDA has also greenlit 23andMe’s test for two variants that influence MUTYH-associated polyposis. This is a rare condition that generally increases the risk of developing colorectal cancer. Learn more about this test in our report.